share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  2024/06/24 17:05

Moomoo AI 已提取核心信息

Illumina has successfully completed the spin-off of GRAIL, transforming it into an independent, publicly traded company. The distribution involved approximately 85.5% of GRAIL's outstanding shares, with shareholders receiving one GRAIL share for every six Illumina shares held as of June 13, 2024. Illumina maintains a 14.5% ownership stake in GRAIL.GRAIL will begin trading on Nasdaq under the ticker symbol "GRAL" on June 25, 2024. To support the spin-off, Illumina secured a $750 million senior unsecured term loan facility at a 6.7% borrowing rate, using the proceeds along with cash to fund GRAIL's balance sheet. The separation was structured to be tax-free for U.S. shareholders, except for cash received in lieu of fractional shares.Illumina announced it will release Q2 2024 results on August 6 and host a virtual Strategy Update on August 13. CEO Jacob Thaysen emphasized that while GRAIL is no longer part of Illumina, the company will continue supporting GRAIL's cancer detection technology through sequencing technology and services.
Illumina has successfully completed the spin-off of GRAIL, transforming it into an independent, publicly traded company. The distribution involved approximately 85.5% of GRAIL's outstanding shares, with shareholders receiving one GRAIL share for every six Illumina shares held as of June 13, 2024. Illumina maintains a 14.5% ownership stake in GRAIL.GRAIL will begin trading on Nasdaq under the ticker symbol "GRAL" on June 25, 2024. To support the spin-off, Illumina secured a $750 million senior unsecured term loan facility at a 6.7% borrowing rate, using the proceeds along with cash to fund GRAIL's balance sheet. The separation was structured to be tax-free for U.S. shareholders, except for cash received in lieu of fractional shares.Illumina announced it will release Q2 2024 results on August 6 and host a virtual Strategy Update on August 13. CEO Jacob Thaysen emphasized that while GRAIL is no longer part of Illumina, the company will continue supporting GRAIL's cancer detection technology through sequencing technology and services.
全球领先的DNA测序和基于芯片技术的公司Illumina Inc.已成功完成GRAIL Inc.的分拆，后者是一家专注于早期癌症检测的医疗保健公司。将约85.5%的GRAIL优先股分配给Illumina的股东，最终于2024年6月24日完成，GRAIL成为了纳斯达克上的独立公开交易的公司，股票代码为“GRAL”。Illumina在分拆后仍持有GRAIL大约14.5%的股权。该分拆通过向Illumina股东分配股份完成，每6股Illumina普通股配发1股GRAIL普通股，配股日为2024年6月13日。该交易未涉及任何由Illumina股东提出的考虑或股份交换。在分拆过程中，Illumina和G...展开全部
全球领先的DNA测序和基于芯片技术的公司Illumina Inc.已成功完成GRAIL Inc.的分拆，后者是一家专注于早期癌症检测的医疗保健公司。将约85.5%的GRAIL优先股分配给Illumina的股东，最终于2024年6月24日完成，GRAIL成为了纳斯达克上的独立公开交易的公司，股票代码为“GRAL”。Illumina在分拆后仍持有GRAIL大约14.5%的股权。该分拆通过向Illumina股东分配股份完成，每6股Illumina普通股配发1股GRAIL普通股，配股日为2024年6月13日。该交易未涉及任何由Illumina股东提出的考虑或股份交换。在分拆过程中，Illumina和GRAIL签署了多项协议，规定了分拆行动和管辖它们之间的后分拆关系，包括分离和分配协议，税务事项协议，员工事项协议，股东和注册权协议，以及修正的供应和商业化协议。Illumina还宣布即将举行两项活动，包括2024年第二季度财务业绩公布，定于8月6日进行，以及8月13日的虚拟策略更新。该公司还获得了7.5亿美元的信贷额度，以支持GRAIL平衡表的现金流。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    ProPhase Labs
    PRPH
    -- 0.441
    GeneDx Holdings
    WGS
    -- 101.825
    Neuronetics
    STIM
    -- 4.705
    OncoCyte
    OCX
    -- 2.7550
    Personalis
    PSNL
    -- 5.920
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。